Oncology Buy-and-Bill Cash Flow: Financing Drug Inventory
Managing oncology buy-and-bill cash flow is one of the biggest financial challenges in community cancer care. Under the buy-and-bill model, a practice purchases infused and injected drugs, administers them to patients and then waits for payers to reimburse it. The practice carries the cost of those drugs, sometimes for an extended period, before any money comes back.
For a growing practice, that gap can tie up a large amount of cash and leave little room for payroll, rent and other expenses. This article explains where the pressure comes from and how working capital financing may help. Drug reimbursement rules vary by payer, and nothing here is legal, tax, billing or compliance advice. Qualified billing professionals and accountants should be part of any cash flow plan.
How the Buy-and-Bill Cycle Works
In a typical cycle, the practice:
- Orders drugs from a distributor or specialty supplier, often on payment terms
- Stores and manages inventory on site
- Administers treatment according to each patient’s care plan
- Submits claims to Medicare, Medicaid or commercial insurers
- Waits for payment, handles denials and collects patient balances
When supplier payment is due before reimbursement arrives, the practice must fund the difference from its own cash or from credit.
Why the Gap Can Grow
Several factors can widen the distance between paying for drugs and being paid for them:
- Higher-cost therapies: newer drugs may cost far more per dose, increasing the cash tied up in each patient
- Patient growth: adding patients, physicians or infusion chairs means buying more inventory up front
- Prior authorization and denials: delays and appeals can stretch the time to payment
- Patient responsibility: coinsurance and deductibles may take longer to collect
- Payer changes: new contracts, enrollments or ownership changes may pause or delay claims
Because Medicare is often the largest payer, changes to Part B drug payment policy can also affect margins. Our article on oncology practice payer mix discusses how lenders view that exposure.
Signs Your Oncology Buy-and-Bill Cash Flow Needs Support
Practices may benefit from a working capital plan when they notice:
- Drug supplier invoices regularly coming due before related claims are paid
- Owners delaying their own compensation to cover inventory
- Difficulty taking on new patients or new therapies because of cash constraints
- Reliance on short-term, high-cost obligations to cover gaps
- Accounts receivable growing faster than revenue
These signs do not necessarily mean the practice is unhealthy. They often reflect growth that the existing cash position was never designed to support.
Working Capital Lines of Credit
A revolving line of credit is one of the most flexible tools for buy-and-bill timing. The practice draws when supplier payments are due and repays as reimbursement arrives, paying interest only on what is outstanding. Lenders generally review historical cash flow, accounts receivable quality, payer mix and the practice’s overall debt load when sizing a line.
Our working capital solutions page describes the range of options available to healthcare businesses, from revolving lines to term financing.
Matching the Facility to the Need
A line of credit sized for today’s patient volume may not fit next year’s. When requesting a line, practices may want to show lenders how drug purchases change as volume grows, how long claims typically remain outstanding and how the line would be paid down. A facility that reflects the practice’s real purchasing cycle can reduce the temptation to rely on costly short-term fixes.
Term loans may also play a role when the need is permanent rather than seasonal, such as funding a higher baseline level of inventory after a practice adds physicians.
Other Ways Practices Manage Drug Inventory Costs
Financing is only part of the picture. Many practices also look at operational steps, ideally with input from their accountants and pharmacy staff:
- Tracking inventory closely to avoid overstocking high-cost drugs
- Reviewing supplier payment terms and purchasing arrangements
- Strengthening prior authorization and claim follow-up processes
- Monitoring accounts receivable aging by payer
- Planning collections of patient balances
Billing and reimbursement decisions should be reviewed by qualified billing or compliance professionals.
When Expansion Increases the Need
Adding chairs, physicians or new sites often brings a step up in drug purchases before new revenue arrives. If you are planning an oncology infusion suite expansion or adding oncology in-office dispensing, budgeting for inventory and receivables is as important as budgeting for construction and equipment.
Cleaning Up Short-Term Debt
Some practices bridge inventory gaps with a mix of credit cards, supplier extensions and short-term advances. Over time, those obligations can become costly and complicated to manage. In some cases, restructuring debt may improve monthly cash flow. Our article on oncology practice refinance options explains what lenders consider. Whether any obligation can be refinanced depends on its terms, the practice’s cash flow and lender review.
Preparing for a Working Capital Request
Lenders reviewing a line of credit request may ask for recent financial statements, tax returns, accounts receivable aging, a summary of drug purchases by month and a schedule of existing debt. A brief explanation of the buy-and-bill cycle and how the line will be used can help a lender understand the request. Every loan is subject to approval, and nothing here is a commitment to lend.
Final Thoughts
Oncology buy-and-bill cash flow pressure is a structural feature of community oncology, not a sign of poor management. With a clear view of inventory, receivables and payer timing, and an appropriately sized working capital facility, many practices can treat more patients without letting cash shortfalls drive decisions.
US Medical Funding helps oncology practices finance drug inventory and day-to-day operations. Learn more about our oncology working capital and lines of credit.
